CA2223643C - Sustained-release formulation of d-threo-methylphenidate - Google Patents

Sustained-release formulation of d-threo-methylphenidate Download PDF

Info

Publication number: CA2223643C
Authority: CA; Canada
Prior art keywords: methylphenidate; formulation; threo; sustained; use according
Prior art date: 1995-07-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002223643A

Other languages

English (en)

French (fr)

Other versions

CA2223643A1 (en

Inventor

Helen Frances Baker

Julian Clive Gilbert

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Celltech Pharma Europe Ltd

Original Assignee

Medeva Europe Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-14

Filing date

1996-07-15

Publication date

2003-12-23

1996-07-15 Application filed by Medeva Europe Ltd filed Critical Medeva Europe Ltd

1997-02-06 Publication of CA2223643A1 publication Critical patent/CA2223643A1/en

2003-12-23 Application granted granted Critical

2003-12-23 Publication of CA2223643C publication Critical patent/CA2223643C/en

2016-07-15 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 54
238000009472 formulation Methods 0.000 title claims abstract description 53
238000013268 sustained release Methods 0.000 title claims abstract description 25
239000012730 sustained-release form Substances 0.000 title claims abstract description 25
DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 title claims abstract description 20
229960001042 dexmethylphenidate Drugs 0.000 title claims abstract description 20
125000003192 dTMP group Chemical group 0.000 claims abstract description 30
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 15
229960001344 methylphenidate Drugs 0.000 claims description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
208000035475 disorder Diseases 0.000 claims description 11
210000002966 serum Anatomy 0.000 claims description 10
238000000576 coating method Methods 0.000 claims description 9
239000011248 coating agent Substances 0.000 claims description 8
230000001055 chewing effect Effects 0.000 claims description 6
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 5
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
206010067948 Compulsive shopping Diseases 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
229940035676 analgesics Drugs 0.000 claims description 3
239000000730 antalgic agent Substances 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
230000003533 narcotic effect Effects 0.000 claims description 3
206010028714 Narcolepsy and hypersomnia Diseases 0.000 claims 2
239000003085 diluting agent Substances 0.000 claims 1
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000003826 tablet Substances 0.000 description 4
239000011149 active material Substances 0.000 description 3
229940125368 controlled substance Drugs 0.000 description 3
239000000599 controlled substance Substances 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000004480 active ingredient Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229960001033 methylphenidate hydrochloride Drugs 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
239000012466 permeate Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
208000030507 AIDS Diseases 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009513 drug distribution Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
DUGOZIWVEXMGBE-OLZOCXBDSA-N methyl (S)-phenyl[(R)-piperidin-2-yl]acetate Chemical compound C([C@@H]1[C@@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-OLZOCXBDSA-N 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002294 pubertal effect Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Hydrogenated Pyridines (AREA)

CA002223643A 1995-07-14 1996-07-15 Sustained-release formulation of d-threo-methylphenidate Expired - Fee Related CA2223643C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9514451.5A GB9514451D0 (en)	1995-07-14	1995-07-14	Sustained-release formulation
GB9514451.5		1995-07-14
PCT/GB1996/001690 WO1997003673A1 (en)	1995-07-14	1996-07-15	Sustained-release formulation of d-threo-methylphenidate

Publications (2)

Publication Number	Publication Date
CA2223643A1 CA2223643A1 (en)	1997-02-06
CA2223643C true CA2223643C (en)	2003-12-23

Family

ID=10777685

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002223643A Expired - Fee Related CA2223643C (en)	1995-07-14	1996-07-15	Sustained-release formulation of d-threo-methylphenidate

Country Status (17)

Country	Link
US (1)	US5874090A (2)
EP (1)	EP0841928B1 (2)
JP (1)	JPH11509228A (2)
KR (1)	KR100481416B1 (2)
AT (1)	ATE224715T1 (2)
AU (1)	AU702371B2 (2)
CA (1)	CA2223643C (2)
CZ (1)	CZ285956B6 (2)
DE (1)	DE69623970T2 (2)
DK (1)	DK0841928T3 (2)
ES (1)	ES2186790T3 (2)
GB (1)	GB9514451D0 (2)
HU (1)	HU224314B1 (2)
MX (1)	MX9800394A (2)
PT (1)	PT841928E (2)
SK (1)	SK281569B6 (2)
WO (1)	WO1997003673A1 (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7115631B2 (en)	1995-12-04	2006-10-03	Celgene Corporation	Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US7431944B2 (en)	1995-12-04	2008-10-07	Celgene Corporation	Delivery of multiple doses of medications
US7459560B2 (en)	1997-05-22	2008-12-02	Celgene Corporation	Processes and intermediates for resolving piperidyl acetamide stereoisomers

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6440457B1 (en) *	1993-05-27	2002-08-27	Alza Corporation	Method of administering antidepressant dosage form
EP0840610A1 (en)	1995-07-14	1998-05-13	Medeva Europe Limited	Composition comprising d-threo-methylphenidate and another drug
US7081238B2 (en) *	1995-11-03	2006-07-25	The President And Fellows Of Harvard College	Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US5908850A (en) *	1995-12-04	1999-06-01	Celgene Corporation	Method of treating attention deficit disorders with d-threo methylphenidate
US5922736A (en) *	1995-12-04	1999-07-13	Celegene Corporation	Chronic, bolus administration of D-threo methylphenidate
US6355656B1 (en) *	1995-12-04	2002-03-12	Celgene Corporation	Phenidate drug formulations having diminished abuse potential
US5733756A (en) *	1996-01-05	1998-03-31	Celgene Corporation	Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US6919373B1 (en)	1996-11-12	2005-07-19	Alza Corporation	Methods and devices for providing prolonged drug therapy
US20020102291A1 (en) *	1997-12-15	2002-08-01	Noven Pharmaceuticals, Inc.	Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6322819B1 (en)	1998-10-21	2001-11-27	Shire Laboratories, Inc.	Oral pulsed dose drug delivery system
US20090149479A1 (en) *	1998-11-02	2009-06-11	Elan Pharma International Limited	Dosing regimen
CA2348871C (en) *	1998-11-02	2009-04-14	John G. Devane	Multiparticulate modified release composition
US20060240105A1 (en) *	1998-11-02	2006-10-26	Elan Corporation, Plc	Multiparticulate modified release composition
US7083808B2 (en)	1998-12-17	2006-08-01	Euro-Celtique S.A.	Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) *	1998-12-17	2004-01-06	Euro-Celtique, S.A.	Controlled/modified release oral methylphenidate formulations
US6419960B1 (en)	1998-12-17	2002-07-16	Euro-Celtique S.A.	Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6127385A (en) *	1999-03-04	2000-10-03	Pharmaquest Limited	Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) *	1999-03-04	2002-05-28	Pharmaquest Limited	Method of treating depression using 1-threo-methylphenidate
JP2002541092A (ja)	1999-04-06	2002-12-03	ファーマクエスト・リミテッド	メチルフェニデートのパルス性送達のための薬学的投薬形態
US20030170181A1 (en) *	1999-04-06	2003-09-11	Midha Kamal K.	Method for preventing abuse of methylphenidate
US7553478B2 (en) *	1999-05-12	2009-06-30	President And Fellows Of Harvard College	Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
GB9913458D0 (en) *	1999-06-09	1999-08-11	Medeva Europ Ltd	The therapeutic use of d-threo-methylphenidate
US20100143248A1 (en) *	1999-06-28	2010-06-10	President And Fellows Of Harvard College	Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level
ATE526950T1 (de)	1999-10-29	2011-10-15	Euro Celtique Sa	Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
JP3856283B2 (ja) *	2000-02-14	2006-12-13	シャープ株式会社	固体撮像装置および撮像装置の駆動方法
US6221883B1 (en) *	2000-04-12	2001-04-24	Ross Baldessarini	Method of dopamine inhibition using l-threo-methylphenidate
EP1163907B1 (en) *	2000-06-17	2006-04-12	Pharmaquest Limited	Use of l-threo-methylphenidate for the manufacture of a medicament for the treatment of depression
US7674480B2 (en) *	2000-06-23	2010-03-09	Teva Pharmaceutical Industries Ltd.	Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
EP2283829A1 (en)	2000-10-30	2011-02-16	Euro-Celtique S.A.	Controlled release hydrocodone formulations
US20020187192A1 (en) *	2001-04-30	2002-12-12	Yatindra Joshi	Pharmaceutical composition which reduces or eliminates drug abuse potential
US20030068375A1 (en)	2001-08-06	2003-04-10	Curtis Wright	Pharmaceutical formulation containing gelling agent
US20030049272A1 (en) *	2001-08-30	2003-03-13	Yatindra Joshi	Pharmaceutical composition which produces irritation
US6638533B2 (en)	2002-01-03	2003-10-28	George Krsek	Pulse dosage formulations of methylphenidate and method to prepare same
US20050232995A1 (en) *	2002-07-29	2005-10-20	Yam Nyomi V	Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050208132A1 (en) *	2002-07-29	2005-09-22	Gayatri Sathyan	Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20080220074A1 (en) *	2002-10-04	2008-09-11	Elan Corporation Plc	Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7988993B2 (en) *	2002-12-09	2011-08-02	Andrx Pharmaceuticals, Inc.	Oral controlled release dosage form
US20050239830A1 (en) *	2004-04-26	2005-10-27	Vikram Khetani	Methods of diminishing co-abuse potential
US20060121112A1 (en) *	2004-12-08	2006-06-08	Elan Corporation, Plc	Topiramate pharmaceutical composition
JP2008523097A (ja) *	2004-12-09	2008-07-03	セルジーン・コーポレーション	Ｄ−トレオメチルフェニデートを用いた治療
GB0507298D0 (en)	2005-04-11	2005-05-18	Novartis Ag	Organic compounds
JP2008535922A (ja) *	2005-04-12	2008-09-04	エラン・ファルマ・インターナショナル・リミテッド	細菌感染を治療するためのセファロスポリンを含む放出制御組成物
WO2007037790A2 (en) *	2005-06-08	2007-04-05	Elan Corporation, Plc	Modified release famciclovir compositions
ATE536867T1 (de)	2006-03-16	2011-12-15	Tris Pharma Inc	Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
US8846100B2 (en)	2006-05-12	2014-09-30	Shire Llc	Controlled dose drug delivery system
US8709477B2 (en) *	2009-08-13	2014-04-29	Kremers Urban Pharmaceuticals, Inc`	Pharmaceutical dosage form
US8623409B1 (en)	2010-10-20	2014-01-07	Tris Pharma Inc.	Clonidine formulation
US8287903B2 (en)	2011-02-15	2012-10-16	Tris Pharma Inc	Orally effective methylphenidate extended release powder and aqueous suspension product
US10905652B2 (en)	2011-03-23	2021-02-02	Ironshore Pharmaceuticals & Development, Inc.	Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en)	2011-03-23	2019-05-21	Ironshore Pharmaceuticals & Development, Inc.	Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en)	2011-03-23	2016-03-15	Ironshore Pharmaceuticals & Development, Inc.	Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en)	2011-03-23	2015-09-01	Ironshore Pharmaceuticals & Development, Inc.	Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en)	2011-03-23	2017-03-28	Ironshore Pharmaceuticals & Development, Inc.	Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en)	2011-03-23	2014-12-23	Ironshore Pharmaceuticals & Development, Inc.	Methods for treatment of attention deficit hyperactivity disorder
US9498447B2 (en)	2011-03-23	2016-11-22	Ironshore Pharmaceuticals & Development, Inc.	Compositions for treatment of attention deficit hyperactivity disorder
BR112013024401B1 (pt)	2011-03-23	2022-01-11	Ironshore Pharmaceuticals & Development, Inc	Composição farmacêutica sólida oral compreendendo um ingrediente ativo estimulante do sistema nervoso central e o uso terapêutico da mesma
US11241391B2 (en)	2011-03-23	2022-02-08	Ironshore Pharmaceuticals & Development, Inc.	Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en)	2011-03-23	2015-01-06	Ironshore Pharmaceuticals & Development, Inc.	Compositions for treatment of attention deficit hyperactivity disorder
AU2013302657B2 (en)	2012-08-15	2018-08-09	Tris Pharma, Inc.	Methylphenidate extended release chewable tablet
CA2936741C (en)	2014-10-31	2018-11-06	Purdue Pharma	Methods and compositions particularly for treatment of attention deficit disorder
US11590228B1 (en)	2015-09-08	2023-02-28	Tris Pharma, Inc	Extended release amphetamine compositions
US11590081B1 (en)	2017-09-24	2023-02-28	Tris Pharma, Inc	Extended release amphetamine tablets
US12458592B1 (en)	2017-09-24	2025-11-04	Tris Pharma, Inc.	Extended release amphetamine tablets
KR102174787B1 (ko)	2018-11-14	2020-11-05	호서대학교 산학협력단	재사용이 가능한 다용도 로드 및 이를 갖는 약물 투여기
US10722473B2 (en)	2018-11-19	2020-07-28	Purdue Pharma L.P.	Methods and compositions particularly for treatment of attention deficit disorder
US11918689B1 (en)	2020-07-28	2024-03-05	Tris Pharma Inc	Liquid clonidine extended release composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2507631A (en) *	1944-01-19	1950-05-16	Ciba Pharm Prod Inc	Pyridine and piperidine compounds and process of making same
US2838519A (en) *	1953-12-23	1958-06-10	Ciba Pharm Prod Inc	Process for the conversion of stereoisomers
US2957880A (en) *	1953-12-23	1960-10-25	Ciba Pharm Prod Inc	Process for the conversion of stereoisomers
US4192827A (en) *	1974-06-27	1980-03-11	Ciba-Geigy Corporation	Water-insoluble hydrophilic copolymers
US5583140A (en) *	1995-05-17	1996-12-10	Bencherif; Merouane	Pharmaceutical compositions for the treatment of central nervous system disorders

1995
- 1995-07-14 GB GBGB9514451.5A patent/GB9514451D0/en active Pending
1996
- 1996-07-15 DE DE69623970T patent/DE69623970T2/de not_active Expired - Lifetime
- 1996-07-15 HU HU9802252A patent/HU224314B1/hu not_active IP Right Cessation
- 1996-07-15 CA CA002223643A patent/CA2223643C/en not_active Expired - Fee Related
- 1996-07-15 EP EP96924083A patent/EP0841928B1/en not_active Expired - Lifetime
- 1996-07-15 AT AT96924083T patent/ATE224715T1/de active
- 1996-07-15 JP JP9506412A patent/JPH11509228A/ja not_active Ceased
- 1996-07-15 AU AU64661/96A patent/AU702371B2/en not_active Ceased
- 1996-07-15 WO PCT/GB1996/001690 patent/WO1997003673A1/en not_active Ceased
- 1996-07-15 PT PT96924083T patent/PT841928E/pt unknown
- 1996-07-15 DK DK96924083T patent/DK0841928T3/da active
- 1996-07-15 ES ES96924083T patent/ES2186790T3/es not_active Expired - Lifetime
- 1996-07-15 SK SK29-98A patent/SK281569B6/sk not_active IP Right Cessation
- 1996-07-15 US US08/679,875 patent/US5874090A/en not_active Expired - Lifetime
- 1996-07-15 CZ CZ9892A patent/CZ285956B6/cs not_active IP Right Cessation
- 1996-07-15 KR KR10-1998-0700286A patent/KR100481416B1/ko not_active Expired - Fee Related
1998
- 1998-01-13 MX MX9800394A patent/MX9800394A/es not_active IP Right Cessation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7115631B2 (en)	1995-12-04	2006-10-03	Celgene Corporation	Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US7431944B2 (en)	1995-12-04	2008-10-07	Celgene Corporation	Delivery of multiple doses of medications
US7459560B2 (en)	1997-05-22	2008-12-02	Celgene Corporation	Processes and intermediates for resolving piperidyl acetamide stereoisomers

Also Published As

Publication number	Publication date
DE69623970T2 (de)	2003-06-05
JPH11509228A (ja)	1999-08-17
GB9514451D0 (en)	1995-09-13
SK281569B6 (sk)	2001-05-10
DE69623970D1 (de)	2002-10-31
CA2223643A1 (en)	1997-02-06
EP0841928A1 (en)	1998-05-20
WO1997003673A1 (en)	1997-02-06
DK0841928T3 (da)	2003-01-27
SK2998A3 (en)	1998-07-08
AU6466196A (en)	1997-02-18
KR19990028984A (ko)	1999-04-15
HU224314B1 (hu)	2005-07-28
AU702371B2 (en)	1999-02-18
MX9800394A (es)	1998-09-30
KR100481416B1 (ko)	2005-07-29
EP0841928B1 (en)	2002-09-25
ATE224715T1 (de)	2002-10-15
US5874090A (en)	1999-02-23
HUP9802252A3 (en)	1999-04-28
CZ9298A3 (cs)	1998-06-17
CZ285956B6 (cs)	1999-12-15
HUP9802252A2 (hu)	1999-01-28
PT841928E (pt)	2002-12-31
ES2186790T3 (es)	2003-05-16

Legal Events

Date	Code	Title	Description
1998-07-28	EEER	Examination request
2014-08-26	MKLA	Lapsed	Effective date: 20140715

Publication	Publication Date	Title
EP0841928B1 (en)	2002-09-25	Sustained-release formulation of d-threo-methylphenidate
CA2306333C (en)	2006-10-10	Oral morphine multiparticulate formulation
EP1001772B1 (en)	2005-10-12	Improved delivery of multiple doses of medications
EP2243475B1 (en)	2016-01-13	Combination of memantine and donepezil for treatment of CNS disorders
AU708873B2 (en)	1999-08-12	Composition comprising d-threo-methylphenidate and another drug
EP1191924A4 (en)	2005-02-09	PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT ADMINISTRATION OF (D-THREO) -METHYLPHENIDATE AND A SECOND STIMULANT OF THE CENTRAL NERVOUS SYSTEM
MX2007006120A (es)	2007-12-07	Metodo y composicion para administrar a un sujeto un antagonista del receptor de nmda.
CA2553156A1 (en)	2005-05-12	Composition and dosage form for sustained effect of levodopa
US6638533B2 (en)	2003-10-28	Pulse dosage formulations of methylphenidate and method to prepare same
FI100303B (fi)	1997-11-14	Menetelmä suun kautta annettavan buspironin ja sen suolan valmistamise ksi
ES2703874T3 (es)	2019-03-12	Psicoestimulante que contiene una composición farmacéutica
CA2465077C (en)	2011-05-17	Improved delivery of multiple doses of medications
JP2008520607A (ja)	2008-06-19	（＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール配合の医薬組成物
CA2558783A1 (en)	1999-04-29	Oral morphine multiparticulate formulation
HK1106711B (en)	2011-07-08	Methods and compositions for treatment of cns disorders

CA2223643C - Sustained-release formulation of d-threo-methylphenidate - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (2)

Family

ID=10777685

Family Applications (1)

Country Status (17)

Cited By (3)

Families Citing this family (67)

Family Cites Families (5)

Cited By (3)

Also Published As

Similar Documents

Legal Events